Idiopathic Pulmonary Fibrosis (IPF) progression can begin nearly a decade before symptoms manifest, according to new modeling research. This chronic lung disease causes progressive scarring of lung tissue, but its early trajectory has been poorly understood until now.
Researchers analyzed pulmonary function data from two patient cohorts, tracking four parameters over time. They estimated disease progression relative to a point where diffusion capacity for carbon monoxide (DLCO) fell to 70% of predicted.
DLCO declined measurably about 10 years before this onset point. Forced vital capacity (FVC) followed a different pattern, remaining near normal five years before onset but dropping substantially five years after. The rate of FVC loss was significantly faster post-onset compared to pre-onset.
These findings suggest IPF follows a predictable, staged physiological decline. Early DLCO reduction may be the first detectable phase. The results have direct implications for clinical trials, suggesting that identifying patients in earlier stages and using DLCO as an endpoint could improve the detection of treatment effects.